Innovative approaches to clinical development and trial design

Annali dell'Istituto Superiore di Sanita

Volumn 47, Issue 1, 2011, Pages 8-13

  Orloff, John J ^a   Stanski, Donald ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical trial; Drug approval; Pharmaceutical preparations

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); HUMAN; METHODOLOGY; SAMPLE SIZE; STATISTICAL MODEL; STATISTICS;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, STATISTICAL; PHARMACOLOGY, CLINICAL; RESEARCH DESIGN; SAMPLE SIZE;

EID: 79953111778     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN-11-01-03     Document Type: Article

References (36)

1. Booth B, Zemmel R. Prospects for productivity. Nature Rev Drug Discov 2004;3:451-6. (Pubitemid 38618127)
2. Gilbert J, Henske P, Singh A. Rebuilding big pharma's business model. In Vivo 2003;21:1-4.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Discov 2004:3:711-6.
4. Budget US Govt., App., FY 1993-2003.
5. Parexel's Pharmaceutical R&D Statistical Sourcebook 2002/2003 (Parexel International, Waltham, USA, 2003).
6. Adams CP, Brantner VV. Spending on new drug development. Health Econ 2009;19:130-41.
7. DiMasi J A, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85. (Pubitemid 36279392)
8. Adams C, Brantner VV. Estimating the cost of new drug development: is it really $ 802 million? Health Aff 2006;2:420-8. (Pubitemid 43529550)
9. Pharmaceutical R&D Factbook 2007. London, UK: CMR International; 2007.
10. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Ann Rev Pharmacol Toxicol 2000;40:67-95. (Pubitemid 30340674)
11. Lalonde RL, et al. Model-based drug development. Clin Pharmacol Ther 2007;82:21-32. (Pubitemid 46950619)
12. Breimer DD, Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modeling concepts in drug development. The "Wooden Shoe" paradigm. Clin Pharmacokinet 1997;32:259-67. (Pubitemid 27160610)
13. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic/pharmacodynamic modeling- a new classification of biomarkers. Pharm Res 2005;22:1432-7. (Pubitemid 41215882)
14. Holford NHG, Kimko HC, Monteleone JPR, Peck CC. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000;40:209-34. (Pubitemid 30340680)
15. Miller R, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005;32:185-97. (Pubitemid 41712739)
16. Berry DA. Bayesian statistics. Med Decis Making 2006;26: 429-30. (Pubitemid 44410293)
17. Müller P, Berry DA, Grieve AP, Smith M, Krams M. Simulation-based sequential Bayesian design. J Stat Plan Inference 2007;137:3140-50.
18. Wang Y, Bhattaram VA, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JV. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA Pharmacometrics during 2004-2006. J Clin Pharmacol 2008;48(2):146-56.
19. Gobburu J. Disease models. Clin Adv Hematol Oncol 2008; 6(4):241-2.
20. US Food and Drug Administration. Division of Pharmacometrics. Selected pharmacosmetics review, guidance and presentations. Available from: www.fda.gov/AboutFDA/CentersOffices/ CDER/ucm167032.htm.
21. Goggin T, et al. Modeling and simulation of clinical trials: an industrial perspective. In:Simulation for designing of clinical trials. Kimko HC, Duffull SB (Ed.). New York, USA: Marcel Dekker; 2002.
22. Reigner BG, et al. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffman La Roche. Clin Pharmacokinet 1997;33:142-52. (Pubitemid 27336953)
23. Lachmann HJ, et al. Use of canakinumab in the cryopyrin- associated periodic syndrome. N Engl J Med 2009;360:2416-25.
24. Berry DA. Bayesian clinical trials. Nature Rev Drug Discov 2006;5:27-36.
25. Berry DA. Introduction to Bayesian methods. III. Use and interpretation of Bayesian tools in design and analysis. Clin Trials 2005;2:295-300. (Pubitemid 41306270)
26. Berry DA. Adaptive trial design. Clin Adv Hematol Oncol 2007;5:522-4. (Pubitemid 47499908)
27. Krams M, et al. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop. J Biopharm Stat 2007;17:957-64. (Pubitemid 350135823)
28. Gallo P, et al. Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group. J Biopharm Stat 2006;16:275-83.
29. Bornkamp B, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2007;17:965-95. (Pubitemid 350135825)
30. Weir CJ, Spiegelhalter DJ, Grieve AP. Flexible design and efficient implementation of adaptive dose-finding studies. J Biopharm Stat 2007;17:1033-50. (Pubitemid 350135833)
31. Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless Phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J 2006;48:623-34. (Pubitemid 44367905)
32. Mehta CR, Patel NR. Adaptive, group sequential and decision theoretic approaches to sample size determination. Stat Med 2006;25:3250-69. (Pubitemid 44489392)
33. Chuang-Stein C, Anderson K, Gallo P, Collins S. Sample size reestimation: a review and recommendations. Drug Inf J 2006;40:475-84. (Pubitemid 44721125)
34. Golub HL. The need for more efficient clinical trials. Stat Med 2006;25:3231-5. (Pubitemid 44489389)
35. Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003;90:367-78. (Pubitemid 39047164)
36. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, Ette E, Gallo P, Hirsch G, Mehta C, Patel N, Sabir S, Springs S, Stanski D, Evers MR, Fleming E, Singh N, Tramontin T, Golub H. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009; 8:945-57.